|
1
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang HY and Sun H: A study on
relationship between Foxp3 gene and ovarian carcinoma. Zhong Guo Fu
You Jian Kang Yan Jiu. 20:595–597. 2009.(In Chinese).
|
|
3
|
Chien CH, Wang FF and Hamilton TC:
Transcriptional activation of c-myc proto-oncogene by estrogen in
human ovarian cancer cells. Mol Cell Endocrinol. 99:11–19. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frost SH, Bäck T, Chouin N, Hultborn R,
Jacobsson L, Elgqvist J, Jensen H, Albertsson P and Lindegren S:
Comparison of 211At-PRIT and 211At-RIT of
ovarian microtumors in a nude mouse model. Cancer Biother
Radiopharm. 28:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zacchetti A, Coliva A, Luison E, et al:
177Lu-labeled MOv18 as compared to 131I- or
90Y-labeled MOv18 has the better therapeutic effect in
eradication of alpha folate receptor-expressing tumor xenografts.
Nucl Med Biol. 36:759–770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gustafsson AM, Bäck T, Elgqvist J, et al:
Comparison of therapeutic efficacy and biodistribution of
213Bi- and 211At-labeled monoclonal antibody
MX35 in an ovarian cancer model. Nucl Med Biol. 39:15–22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winter-Roach BA, Kitchener HC and
Dickinson HO: Adjuvant (post-surgery) chemotherapy for early stage
epithelial ovarian cancer. Cochrane Database Syst Rev.
CD004706:2009. View Article : Google Scholar
|
|
8
|
Scholz C, Heublein S, Lenhard M, Friese K,
Mayr D and Jeschke U: Glycodelin A is a prognostic marker to
predict poor outcome in advanced stage ovarian cancer patients. BMC
Res Notes. 5:5512012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arias-Pulido H, Smith HO, Joste NE,
Bocklage T, Qualls CR, Chavez A, Prossnitz ER and Verschraegen CF:
Estrogen and progesterone receptor status and outcome in epithelial
ovarian cancers and low malignant potential tumors. Gynecol Oncol.
114:480–485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ito K, Utsunomiya H, Niikura H, Yaegashi N
and Sasano H: Inhibition of estrogen actions in human gynecological
malignancies: new aspects of endocrine therapy for endometrial
cancer and ovarian cancer. Mol Cell Endocrinol. 340:161–167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Badia E, Docquier A, Busson M, Lapierre M,
Pujol P, Balaguer P and Cavailles V: Long-term treatment with the
pure anti-estrogen fulvestrant durably remodels estrogen signaling
in BG-1 ovarian cancer cells. J Steroid Biochem Mol Biol.
132:176–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakayama K, Nakayama N, Katagiri H and
Miyazaki K: Mechanisms of ovarian cancer metastasis: biochemical
pathways. Int J Mol Sci. 13:11705–11717. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Azimian-Zavareh V, Hossein G and Janzamin
E: Effect of lithium chloride and antineoplastic drugs on survival
and cell cycle of androgen-dependent prostate cancer LNCap cells.
Indian J Pharmacol. 44:714–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stevens EV, Banet N, Onesto C, Plachco A,
Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J,
Miller CR, Vigil D, Graves LM and Der CJ: RhoGDI2 antagonizes
ovarian carcinoma growth, invasion and metastasis. Small GTPases.
2:202–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palmer TD, Ashby WJ, Lewis JD and Zijlstra
A: Targeting tumor cell motility to prevent metastasis. Adv Drug
Deliver Rev. 63:568–581. 2011. View Article : Google Scholar
|
|
16
|
Song G, Ren J, Stojadinovic A, Chen W,
Sahab Z, Fu SW and Man YG: Conjunction of tumor cells with
lymphocytes: implications for tumor invasion and metastasis. Cancer
Epidemiol. 36:354–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Petrovic M, Jankovic Z, Jaukovic Lj, et
al: Clinical value of immunoscintigraphy in the rectal carcinomas:
immunoscintigraphy of rectal carcinomas. Hepatogastroenterology.
60:1355–1359. 2013.PubMed/NCBI
|
|
18
|
Pagel JM, Appelbaum FR, Eary JF, et al:
131I-anti-CD45antibody plus busulfan and cyclophosphamide before
allogeneic hematopoi-etic cell transplantation for treatment of
acute myeloid leukemia in first re-mission. Blood. 107:2184–2191.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Andersson H, Cederkrantz E, Bäck T, Divgi
C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H,
Lindegren S, Palm S and Hultborn R: Intraperitoneal alpha-particle
radioimmunotherapy of ovarian cancer patients: pharmacokinetics and
dosimetry of 211At-MX35F(ab')2 - a
phase I study. J Nucl Med. 50:1153–1160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Steiner M and Neri D:
Antibody-radionuclide conjugates for cancer therapy: historical
considerations and new trends. Clin Cancer Res. 17:6406–6416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harris M, Wang XG, Jiang Z, Phaeton R,
Koba W, Goldberg GL, Casadevall A and Dadachova E: Combined
treatment of the experimental human papilloma virus-16-positive
cervical and head and neck cancers with cisplatin and
radioimmunotherapy targeting viral E6 oncoprotein. Br J Cancer.
108:859–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
